Accessibility helpSkip to navigationSkip to contentSkip to footer
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign In
  • Home
  • World
    Sections
    • World Home
    • Middle East war
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    Most Read
    • Iran warns of potential change in nuclear doctrine if Israel targets facilities
    • UK executives dump shares on fears of Labour capital gains tax raid
    • Reeves weighs capital gains tax hike to help plug UK’s Budget gap
    • Florida surveys wreckage left by Hurricane Milton
    • French PM Michel Barnier unveils shock therapy in 2025 budget
  • US
    Sections
    • US Home
    • US Economy
    • Investing in America
    • US Companies
    • US Politics & Policy
    • US Presidential Election 2024
    Most Read
    • Iran warns of potential change in nuclear doctrine if Israel targets facilities
    • Florida surveys wreckage left by Hurricane Milton
    • US inflation fell to 2.4% in September
    • Why Kamala Harris chose to appear on the ‘Call Her Daddy’ podcast
    • Trump pledges to end double taxation for expat Americans
  • Companies
    Sections
    • Companies Home
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
    Most Read
    • Starboard plotted a campaign against Pfizer’s chief. Then a blank email dropped in his inbox
    • Private equity groups’ assets struggling under hefty debt loads, Moody’s says
    • Stellantis unveils management shake-up at global car brands
    • The ‘80-hour circuit breaker’: Wall Street banks tackle workloads of junior staff
    • Why Kamala Harris chose to appear on the ‘Call Her Daddy’ podcast
  • Tech
    Sections
    • Tech Home
    • Artificial intelligence
    • Semiconductors
    • Cyber Security
    • Social Media
    Most Read
    • AMD rolls out new AI chip to rival Nvidia
    • Checking out of Hotel California
    • Why Big Tech makes such a poor babysitter
    • How Google plans to deflect and delay a historic break-up threat
    • US weighs Google break-up in landmark antitrust case
  • Markets
    Sections
    • Markets Home
    • Alphaville
    • Markets Data
    • Crypto
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Wealth Management
    • Moral Money
    • ETF Hub
    • Fund Management
    • Trading
    Most Read
    • TD Bank to pay $3bn in US case over money laundering lapses
    • How Russia’s ‘shadow fleet’ gets its ships
    • Warren criticises accounting watchdog over BDO audit failures
    • China’s real intent behind its stimulus inflection
    • Former UBS chief Ralph Hamers joins AI wealth management start-up
  • Climate
  • Opinion
    Sections
    • Opinion Home
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
    Most Read
    • Why Kamala Harris chose to appear on the ‘Call Her Daddy’ podcast
    • The battle of Labour’s three brains
    • The Ritz, London: Is this where I fall back in love with fine dining? — review 
    • How anime took over the world
    • China’s real intent behind its stimulus inflection
  • Lex
  • Work & Careers
    Sections
    • Work & Careers Home
    • Business School Rankings
    • Business Education
    • Europe's Start-Up Hubs
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
    • Working It
    Most Read
    • The ‘80-hour circuit breaker’: Wall Street banks tackle workloads of junior staff
    • Trump pledges to end double taxation for expat Americans
    • Herman Chinery-Hesse, tech entrepreneur, 1963-2024
    • Labour must keep listening to business
    • Would you trust a self-hypnosis app?
  • Life & Arts
    Sections
    • Life & Arts Home
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
    Most Read
    • The Ritz, London: Is this where I fall back in love with fine dining? — review 
    • How anime took over the world
    • South Korean author Han Kang wins Nobel literature prize
    • Introducing Ventete, the world’s first inflatable bike helmet
    • Peter Schlesinger: ‘It was drug-ridden back then — but a wonderful place’
  • HTSI
  1. Companies
  2. Health
  • Healthcare
  • Pharmaceuticals
MenuSearch
  • Home
  • World
  • US
  • Companies
  • Tech
  • Markets
  • Climate
  • Opinion
  • Lex
  • Work & Careers
  • Life & Arts
  • HTSI
Financial Times
SubscribeSign In

Health

  • Thursday, 10 October, 2024
    GSK PLC
    GSK shares jump after drugmaker reaches $2.2bn Zantac settlement

    Agreement over heartburn medicine should help to resolve concerns hanging over UK drugmaker

    Packages of Zantac
  • Thursday, 10 October, 2024
    HTSI
    Would you trust a self-hypnosis app?

    Once an entertainment gimmick, the practice is becoming a powerful wellness tool

  • Thursday, 10 October, 2024
    News in-depthUK employment
    Why are a rising number of young Britons out of work?

    A record 35% of people aged 18-24 were classed as ‘inactive’ this year, driven by a mental health crisis

    Montage shows an anonymous young person against a backdrop of FT data
  • Wednesday, 9 October, 2024
    Work Watch
    Heartbreak leave can help employees recover from shattered relationships

    A bill in the Philippines is trying to secure time off for workers after a break-up. Could it improve productivity elsewhere?

    Montage image of two hands, one above and one below, a breaking heart with tears falling from it
  • Wednesday, 9 October, 2024
    Anjana Ahuja
    Marburg outbreak in Rwanda shows some post-pandemic progress

    It is too early to know whether the prompt response to the virus is enough to turn the tide

    Andy Carter illustration of two scientists working on a vaccine as a virus looms large over them
  • Tuesday, 8 October, 2024
    Healthcare costs
    Obesity drugs could cost US health insurance system $35bn, study finds

    CBO analysis says savings from other health benefits would not offset the expense of weight-loss jabs

    Boxes of Ozempic and Wegovy
  • Monday, 7 October, 2024
    Europe Express
    EU court to hear case on von der Leyen’s texts with Pfizer next month Premium content

    Also in this newsletter: How greener corporate car fleets could boost competitiveness and the climate goals

    Ursula von der Leyen
  • Sunday, 6 October, 2024
    Drugs research
    Regeneron head says weight-loss drugs could cause ‘more harm than good’

    US biotech researches treatments to reduce muscle loss from blockbuster diet medicines

    Weight-loss injection pen parts at the Novo Nordisk A/S production facilities in Hillerod, Denmark
  • Sunday, 6 October, 2024
    Jemima Kelly
    How I learnt to stop worrying and (mostly) love the e-bike

    Unsightly kerbside debris to some, eco-friendly cycles for hire have improved urban journeys

    Illustration of a Lime bike rider
  • Friday, 4 October, 2024
    Data PointsJohn Burn-Murdoch
    We may have passed peak obesity

    Weight loss drugs appear to be having an effect at the population level

    Montage of images. An old fashioned bathroom scale with a red chart line showing the peak and dip of US obesity in the background.
  • Wednesday, 2 October, 2024
    Prime property
    Five homes for sale that are fun for children

    From a Maldives villa with skateboard ramps, zip lines and bowling alley to an East Sussex barn conversion with a treetop play area

    A curved slide leads to an organically shaped swimming pool by the side of a wooden villa. The whole area is surrounded by palm trees.
  • Wednesday, 2 October, 2024
    Science
    Map of adult insect’s brain offers clues on neurological diseases

    International collaboration plotted 149 metres of biological wiring in fruit fly

    Caption: The fruit fly connectome contains a wide range of information, from cell types and synapses to neurotransmitters and network properties. Here, cells are color-coded by their defining chemical messenger. Blue: GABA; yellow: acetylcholine (ACH); pink: glutamate (GLUT).
  • Wednesday, 2 October, 2024
    The Big Read
    Can Eli Lilly become the first $1tn drugmaker?

    The company is thriving as weight-loss drugs boom, but investors see warning signs it has reached ‘peak enthusiasm’

    Montage image of David Ricks, chief executive of Eli Lilly, Zepbound medication and a building with the company’s logo on it
  • Wednesday, 2 October, 2024
    Brooke Masters
    Ozempic is transforming your gym

    Weight-loss drugs and a new focus on wellness are pushing many exercise machines towards obsolescence

    Injection pens of Novo Nordisk’s weight-loss drug Wegovy
  • Wednesday, 2 October, 2024
    House & Home
    Lessons from America’s first ‘war on rats’ summit

    New York City appointed a ‘rat tsar’ and launched ‘rat academies’ — its inaugural National Urban Rat Summit aimed to offer fresh insights to help landlords and renters

  • Wednesday, 2 October, 2024
    Artificial intelligence
    DeepMind and BioNTech build AI lab assistants for scientific research

    Artificial intelligence used to help researchers plan experiments and better predict outcomes

    Montage of Google DeepMind and BioNTech logos with a finger on a smartphone in the foreground and semiconductor chip design in the background
  • Tuesday, 1 October, 2024
    Eli Lilly & Co
    Eli Lilly considers testing weight-loss drugs on people who are not overweight

    Drugmaker’s CEO sees chance to widen use of anti-obesity medications for ‘health maintenance’

    Zepbound  medication
  • Monday, 30 September, 2024
    Roche Holding AG
    Roche plans to launch drugs and slash development costs

    Swiss pharma group is a high spender on R&D but has had misses in Alzheimer’s and cancer

    A Roche Research laboratory
  • Sunday, 29 September, 2024
    Food diet
    Food businesses and investors call on UK to tackle unhealthy diets

    Mandatory reporting and clear road map of reform needed, say retail giants and financial groups

    Beef burgers in a sesame seed bun with chips on the side
  • Saturday, 28 September, 2024
    Bryce Elder
    How to lose sight of what’s important

    From playlists to pressure washers, the internet’s vacant spaces can be refuges in the too-much-information age

    A computer-generated image in blocky, low-definition pixels, of a flaming torch inside a dark underground shaft
  • Friday, 27 September, 2024
    Jo Ellison
    Everyone’s on Ozempic. So why will no one talk about it?

    The fashion world is embracing weight-loss drugs — discreetly

  • Friday, 27 September, 2024
    FT SeriesDon’t miss – HTSI’s most popular stories
    What I learned while being bedbound

    Claudia Donaldson assumed a months-long rest cure would bore her senseless. Instead, she found it transformational

    Point Me Towards, 2022, by Christopher Hartmann
  • Friday, 27 September, 2024
    FT Magazine
    Inside the ‘killer cell’ factory

    The next stage in the war on cancer may be enlisting patients’ own blood cells to fight the disease

    Two men dressed in business suits standing side by side under a tree
  • Friday, 27 September, 2024
    Data PointsJohn Burn-Murdoch
    Out of work and unwell: the worrying rise of young people on benefits

    Data shows increasing numbers in rich countries turning to welfare

    Montage image showing people with their backs turned and a couple of chart lines
  • Thursday, 26 September, 2024
    Anthony McDonnell
    Antimicrobial resistance is dangerous in more ways than one

    The reduced effectiveness of antibiotics risks severe disruption to the global economy

    Staff members work on the production line of penicillin antibiotics
Previous page You are on page 1 Next page

Most Read

  1. Why are a rising number of young Britons out of work?
  2. GSK shares jump after drugmaker reaches $2.2bn Zantac settlement
  3. Marburg outbreak in Rwanda shows some post-pandemic progress
  4. Would you trust a self-hypnosis app?
  5. Obesity drugs could cost US health insurance system $35bn, study finds

Join us at an FT Live event

Discover unmissable flagship events and members only communities to expand your thinking and elevate your career

FT Live
Accelerating Adoption of Health Technologies
Funding models and new partnerships
Wednesday, 30 OctoberBayfront Avenue, Marina Bay Sands, Expo & Convention Centre, Singapore
FT Live
Global Pharma and Biotech Summit
Driving life sciences innovation in a disrupted world
Tuesday, 5 NovemberIn-Person & Online Conference
Explore all events

Useful links

Support

View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

Legal & Privacy

Terms & ConditionsPrivacy PolicyCookie PolicyManage CookiesCopyrightSlavery Statement & Policies

Services

Share News Tips SecurelyIndividual SubscriptionsProfessional SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on XFT ChannelsFT Schools

Tools

PortfolioFT AppFT Digital EditionFT EditAlerts HubBusiness School RankingsSubscription ManagerNews feedNewslettersCurrency Converter

Community & Events

FT Live EventsFT ForumsBoard Director Programme

More from the FT Group

Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2024. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
Edition:International
UK
Subscribe for full access

Top sections

  • Home
  • World
    • Middle East war
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
  • US
    • US Economy
    • Investing in America
    • US Companies
    • US Politics & Policy
    • US Presidential Election 2024
  • Companies
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
  • Tech
    • Artificial intelligence
    • Semiconductors
    • Cyber Security
    • Social Media
  • Markets
    • Alphaville
    • Markets Data
    • Crypto
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Wealth Management
    • Moral Money
    • ETF Hub
    • Fund Management
    • Trading
  • Climate
  • Opinion
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
  • Lex
  • Work & Careers
    • Business School Rankings
    • Business Education
    • Europe's Start-Up Hubs
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
    • Working It
  • Life & Arts
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
  • Personal Finance
    • Property & Mortgages
    • Investments
    • Pensions
    • Tax
    • Banking & Savings
    • Advice & Comment
    • Next Act
  • HTSI
  • Special Reports

FT recommends

  • Alphaville
  • FT Edit
  • Lunch with the FT
  • FT Globetrotter
  • #techAsia
  • Moral Money
  • Visual and data journalism
  • Newsletters
  • Video
  • Podcasts
  • News feed
  • FT Schools
  • FT Live Events
  • FT Forums
  • Board Director Programme
  • myFT
  • Portfolio
  • FT Digital Edition
  • Crossword
  • Our Apps
  • Help Centre
  • Subscribe
  • Sign In